Accelerating Patient Access to Transformative CNS Therapies Through Strategic Market Planning & Pre-Launch Excellence
Launched in Boston in September 2025, the Market Access for CNS Therapeutics Summit maked its debut with an expanded, CNS-specific agenda shaped by industry leaders from Biogen, J&J, Roche, Eisai, and many more. As precision neuroscience, diagnostics, and digital therapeutics reshape the access landscape, this meeting dove deep into payer engagement, diagnostic integration, and post-approval strategy.
With 16+ expert speakers and cutting-edge sessions on biomarker reimbursement, patient navigation, and umbrella trials, attendees gained practical insights to overcome the growing complexity of market access in CNS.
What You Missed in 2025:
End-to-End Market Access Strategy
Learn how to integrate market access considerations early in CNS clinical development to align evidence generation, payer engagement, and commercial success from Phase II through launch.
Real-World Access Insights from Leading Innovators
Gain practical, case-based lessons from companies like Biogen, Johnson & Johnson, Eli Lilly, and Bristol Myers Squibb on navigating complex payer dynamics, stigma, and infrastructure barriers in CNS therapeutic launches.
Tools to Address Payer &
Regulatory Challenges
Discover how to proactively manage formulary access, reimbursement hurdles, and payer scepticism using trial design, real-world data, and strategic payer education.
CNS-Specific Networking & Benchmarking
Build relationships with 50+ senior stakeholders across pharma, payers, diagnostics, and advocacy to benchmark strategies and identify collaboration opportunities unique to the CNS access environment.
Special Focus on Diagnostics, Digital & Precision CNS Care
Explore how diagnostics, digital therapeutics, and biomarker-driven treatments are reshaping access models, and what is required to demonstrate value and secure coverage in these emerging spaces.
Who we met in 2025?
Connect with 60+ market access stakeholders from industry, insurance companies, healthcare providers, and patient advocates, for a comprehensive guide to enabling earlier access to your pipeline of more truly transformative CNS therapeutics.
What Your Peers Have to Say
Check Out the 2025 Agenda
